Provoking a sea change in immunotherapy.go down
A safe non-replicating virus to fight infectious diseases.
- Additive Protection against Congenital CMV
- Congenital Cytomegalovirus: A Now Problem, No, Really Now
- Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity
- Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens
A safe attenuated replicating virus to combat cancer as a single agent or in combination with other therapies.
|Compound||Indication||Target/Antigen||Phase||Discovery DISC||Pre-clinical PREC||Phase 1 1||Phase 2 2||Phase 3 3|
|HB-101 Vaxwave®||Cytomegalovirus (CMV)||GB and PP65||1|
|HB-201 TheraT®||Human papilloma virus (HPV)||E7/E6 viral||1|
|HB-301 TheraT®||Not disclosed||Not disclosed||DISC|
|HB-401 TheraT®||Not disclosed||Not disclosed||DISC|